Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.44Last Year’s EPS
0.43Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 20.74%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, significant expansion in coverage for type 2 diabetes, and successful product innovations. However, challenges included a decline in gross margin due to supply chain issues and an FDA warning letter that required attention. Overall, while there are notable achievements, the presence of significant challenges suggests a balanced sentiment.Company Guidance
During DexCom's First Quarter 2025 Earnings Call, the company reported an organic revenue growth of 14% compared to the first quarter of 2024, with worldwide revenue reaching $1.036 billion, a 12% increase on a reported basis. U.S. revenue grew by 15% to $751 million, while international revenue rose by 7% to $286 million, with organic growth at 12%. The company maintained its full-year revenue guidance of $4.6 billion, representing a 14% growth. DexCom's gross profit margin was 57.5%, down from 61.8% the previous year, primarily due to increased freight costs and inflationary pressures. Despite these challenges, DexCom reaffirmed its full-year guidance for operating margin at approximately 21% and adjusted EBITDA margin at 30%. The company also announced a $750 million share repurchase program, reflecting confidence in its cash flow outlook. DexCom's continued expansion in the type 2 non-insulin patient market, bolstered by broader insurance coverage, contributed to a record level of new customer starts, particularly from this demographic.Strong Organic Revenue Growth
DexCom reported first quarter organic revenue growth of 14% compared to the first quarter of 2024, with U.S. revenue increasing by 15%.
Expansion in Type 2 Diabetes Coverage
DexCom secured coverage for nearly 6 million people with type 2 diabetes who are not on insulin, including coverage from the 3 largest PBMs in the U.S.
Introduction of Over-the-Counter CGM - Stelo
DexCom launched Stelo as the first over-the-counter CGM, attracting customers across the type 2 diabetes, prediabetes, and health and wellness markets.
FDA Clearance for 15 Day Dexcom G7 System
Received FDA clearance for the 15 Day Dexcom G7 System, marking a milestone with improved wear time and accuracy.
Share Repurchase Program
Announced a $750 million share repurchase program, indicating confidence in the company's financial position.
DXCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DXCM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $70.26 | $81.62 | +16.17% |
Feb 13, 2025 | $84.09 | $89.07 | +5.92% |
Oct 24, 2024 | $74.85 | $73.44 | -1.88% |
Jul 25, 2024 | $107.85 | $64.00 | -40.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Dexcom (DXCM) report earnings?
Dexcom (DXCM) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Dexcom (DXCM) earnings time?
Dexcom (DXCM) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DXCM EPS forecast?
DXCM EPS forecast for the fiscal quarter 2025 (Q2) is 0.44.
